Advanced Molecular Diagnostics: Addressing Complicated and Recurrent Urinary Tract Infections through Clinical Metagenomics
Urinary tract infections affect an estimated 404 million people globally each year, including 11 million in the United States. While most UTIs are uncomplicated, a significant subset progresses to complicated or recurrent infection (cUTI/rUTI), particularly in patients with urological abnormalities, immunosuppression, or catheterization. Conventional urine culture — the current diagnostic gold standard — has well-documented limitations. The BIOTIA-ID Urine Test addresses these gaps using clinical metagenomic next-generation sequencing (mNGS) with a proprietary machine learning bioinformatics pipeline (BIOTIA-DX). This white paper details the test's analytical and clinical validation across 1,470+ urine specimens, demonstrated clinical utility in U.S. and international cohorts, and recommended use cases for integration into clinical workflows.
97.2% sensitivity and 99.6% specificity across 1,470 urine specimens; >99.9% sensitivity and specificity across 14,500+ analytes.
In a SUNY Downstate cohort of 200 culture-negative symptomatic patients, BIOTIA-ID detected key uropathogens in 63% of samples — half of which were polymicrobial.
In 70% of those culture-negative cases, the prescribed empirical antibiotic would have had no effect on the actual pathogen detected.
14 antimicrobial resistance gene markers across 6 resistance mechanism classes validated with 100% sensitivity and 99.6% specificity over 597 specimens and 2,395 analytes.
Background
Urinary tract infections are among the most prevalent bacterial infections globally, responsible for an estimated 404 million cases annually worldwide and approximately 11 million cases in the United States alone. While many UTIs are self-limited or uncomplicated, a significant subset progresses to complicated or recurrent infection (cUTI/rUTI), especially in patients with urological abnormalities, immunosuppression, or catheterization. These high-risk populations face increased morbidity, elevated healthcare costs, and a heightened risk of progression to urosepsis, which carries substantial mortality. The limitations of conventional urine culture, the current diagnostic gold standard, have been increasingly recognized in both research and clinical communities. Culture can take 24 to 72 hours for results and lacks sensitivity in detecting fastidious organisms, mixed infections, or pathogens in patients who have received prior antimicrobial therapy. False-negative rates of 30 to 50% in such cases lead to diagnostic uncertainty and empirical use of broad-spectrum antibiotics, which in turn drives antimicrobial resistance and poor outcomes. Next-generation sequencing has emerged as a transformative tool for infectious disease diagnostics. Unlike culture or PCR-based methods, NGS enables hypothesis-free pathogen detection by sequencing all nucleic acids in a clinical sample. The BIOTIA-ID Urine Test was developed as a next-generation sequencing-based metagenomic assay that enables comprehensive, culture-independent identification of uropathogens directly from urine specimens, paired with the proprietary BIOTIA-DX bioinformatics pipeline.
The Standard of Care is Not Enough
Urine culture remains the standard diagnostic tool for UTI detection. It involves growing bacteria on selective media and interpreting colony counts using thresholds originally defined for healthy outpatient women. However, this method is inherently limited by: • Sensitivity: Culture can fail to detect organisms such as anaerobes, fungi, and fastidious bacteria. Candida species, for example, are often missed or simply reported as “yeast” without speciation. • Prior antibiotic use: Culture yield is significantly reduced in patients who have received antibiotics before urine collection, leading to false-negative results despite ongoing infection. • Polymicrobial infections: Mixed cultures are frequently dismissed as contamination, despite evidence that polymicrobial UTIs are clinically significant, particularly in cUTI and catheter-associated UTI cases. • Diagnostic turnaround time: Delays in pathogen identification slow appropriate treatment decisions, especially in sepsis or immunocompromised patients. • Interpretive ambiguity: Culture thresholds (e.g., 10⁵ CFU/mL) were developed for healthy outpatient women and may not be appropriate for hospitalized or catheterized patients. PCR-based assays represent a step forward, offering faster turnaround and improved sensitivity over culture. However, they are inherently limited by their targeted nature: PCR can only detect organisms explicitly included in the assay design and may miss rare or unexpected pathogens. Many PCR panels also fail to account for microbial load or polymicrobial context, and PCR is susceptible to amplification bias. Clinical metagenomic next-generation sequencing (mNGS) allows testing of patient urine samples without the need for culturing. By sequencing genetic material and comparing detected sequences to a comprehensive microbial genome database, mNGS can accurately and rapidly identify pathogens in cUTI/rUTI patient samples that may have atypical pathogens, multiple co-infecting organisms, and complex resistance profiles. The BIOTIA-ID Urine Test is the first mNGS urine test to receive approval across all 50 U.S. states as a laboratory-developed test.
The BIOTIA-ID Urine Test
In a comprehensive analytical and clinical validation study, BIOTIA-ID was tested on 1,470 urine specimens across 65 sequencing runs. The validation followed New York State Department of Health guidelines and included both clinical and contrived specimens, orthogonally validated with culture, qPCR, and Sanger sequencing. • Clinical accuracy: 335 clinical urine specimens were tested with 97.2% sensitivity and 99.6% specificity. Across more than 14,500 analytes in contrived and clinical samples, the test achieved over 99.9% overall sensitivity and specificity. • Specificity: 100% sensitivity and 99.96% specificity for bacterial targets, and 100% sensitivity and specificity for fungal targets, across 69 microbial species and 154 strains. • Analytical sensitivity (limit of detection): assessed for the 16 most frequently found uropathogens to reliably detect pathogens at low, clinically relevant concentrations. • Reproducibility: in studies using 19 diverse microbial pools over multiple days, BIOTIA-ID maintained 100% sensitivity, specificity, and qualitative reproducibility, even across genetically variable strains. • In silico testing: 99.99% sensitivity and specificity, with a 1.7% rate of initial cross-reactivity that bioinformatic refinements reduced to 0.3% false positives. • AMR validation: 14 antimicrobial resistance gene markers across 6 resistance mechanism classes were validated across 597 specimens and 2,395 total analytes, achieving 100% sensitivity and 99.6% specificity. 34.8% of clinical specimens were positive for AMR with 271 analytes detected. In the clinical accuracy study, BIOTIA-ID detected a broader spectrum of pathogens compared with urine culture, primarily key uropathogens (71.8%) but also organisms not usually detectable by standard urine culture methods. 87% of NGS results were concordant with the qPCR and Sanger sequencing comparators.
Demonstrated Clinical Utility
In partnership with State University of New York (SUNY) Downstate, we assessed BIOTIA-ID Urine Test performance on 200 urine specimens from patients with UTI symptoms but negative culture results. The test detected known uropathogens in 63% of culture-negative specimens, 50% of which were single-organism infections and 50% polymicrobial. Retrospective evaluation of patient records found that in 70% of cases the prescribed antimicrobial would have had no effect on the pathogen detected, and in 18% it could have been de-escalated. We also partnered with a private hospital in Southeast Asia to evaluate global applicability, including 382 clinical specimens (228 culture-positive and 154 culture-negative). BIOTIA-ID identified at least one organism in 97.1% of culture-positive samples, with overall organism-level sensitivity of 94.6%, and detected co-infecting organisms in 18.4% of culture-positive samples. In culture-negative samples, BIOTIA-ID identified organisms in 74.0% — the majority anaerobic or fastidious. Among detections not captured by standard culture, 75.2% were anaerobic or fastidious bacteria, and more than half of the remaining organisms were found in polymicrobial infections.
Guidelines for Clinical Implementation
We built a secure patient management guideline to achieve accurate diagnostic stewardship, identify the right patients for the test, and improve outcomes. The BIOTIA-ID Urine Test is intended to be used as a reflex, supplemental, or replacement diagnostic in specific clinical contexts where culture is known to underperform. Recommended use cases include: • Recurrent UTIs (rUTIs): patients with ≥3 UTIs per year or ≥2 in the past six months. • Complicated UTIs (cUTIs): including urinary tract abnormalities, catheter-associated infections, or pyelonephritis. • Culture-negative symptomatic patients: persistent UTI symptoms with negative or inconclusive culture results. • Immunocompromised patients: elderly with co-morbidities (diabetes, dementia, catheterized patients), transplant and oncology patients, or those on immunosuppressive therapy. • Sepsis of unknown origin: when a urinary source of sepsis is suspected but not confirmed by culture.
Integration into Clinical Workflow
UTI diagnosis is a clinical process that combines patient history, presenting symptoms, physical examination, and laboratory findings. The BIOTIA-ID Urine Test can be integrated at multiple points in the patient care pathway: • Initial diagnostic workup: rapid, comprehensive results for high-risk patients or those with prior antibiotic exposure, enabling early targeted therapy. • Post-culture follow-up (reflex test): actionable insights for unresolved infections or culture-negative cases, reducing diagnostic uncertainty. • Antimicrobial stewardship: precision prescribing through accurate pathogen identification and resistance profiling, reducing unnecessary antibiotic use. For symptomatic patients with no known cUTI risk factors and no UTI in the past 6 months, the standard pathway (urinalysis → urine culture → antimicrobial susceptibility testing) remains appropriate. For symptomatic patients with cUTI/rUTI, immunocompromised status, or sepsis of unknown origin, the BIOTIA-ID Urine Test follows urinalysis and a positive urine culture, returning uropathogens and resistance markers from a single test — improving outcomes, lowering risk of complications and recurrence, and improving AMR stewardship.
Challenges in Metagenomic Approaches to UTI
Several companies are marketing laboratory-developed tests directly to consumers, posing challenges for clinicians and patients alike that the BIOTIA-ID Urine Test overcomes. Reporting both pathogenic and commensal microbes — as many tests do — leads to overtreatment of nonpathogenic species and undue patient stress without appropriate clinical context. With subject matter expert consultation, 44 known uropathogens were validated for reporting by the BIOTIA-ID Urine Test. The bioinformatics pipeline includes a proprietary machine learning step trained on real patient specimens with substantial metadata, and filters out commensal microflora and contamination — simplifying clinical decision-making and preventing unnecessary worry. Clinical reports include organism-specific data with classification confidence, and polymicrobial detections are included when clinically relevant. Many tests also purport to offer insight into antimicrobial resistance. The detection of antibiotic resistance genes (ARGs) alone is insufficient to determine resistance: ARGs may be present in commensal species rather than the pathogen detected, may work in tandem to produce different levels of susceptibility, or may be present without conferring functional resistance. Reporting all ARGs in a sample paradoxically threatens appropriate stewardship. In a study using both culture-positive and culture-negative patient samples, the BIOTIA-ID Urine Test's ability to detect ARGs achieved 96–100% accuracy across all examined genes compared with traditional PCR assays. The BIOTIA-DX software was awarded “Best Prediction Accuracy” at the 2025 Critical Assessment of Massive Data Analytics conference, highlighting the rigor of the bioinformatics pipeline.
Conclusion
The BIOTIA-ID Urine Test demonstrates a marked improvement over standard culture methods in sensitivity, specificity, and pathogen breadth, including accurate identification of fastidious, fungal, and polymicrobial infections. Its robust validation and high diagnostic accuracy support its clinical utility in managing complicated, recurrent, and high-risk UTI cases. As UTI diagnostics continue to evolve, the BIOTIA-ID Urine Test offers a precision medicine approach that aligns with the goals of antimicrobial stewardship and improved patient outcomes.
References
- Zeng Z, et al. Global, regional, and national burden of urinary tract infections from 1990 to 2019. World J Urol. 2022;40(3):755-763.
- Yang X, et al. Disease burden and long-term trends of urinary tract infections: A worldwide report. Front Public Health. 2022;10:888205.
- Price TK, et al. The Clinical Urine Culture: Enhanced Techniques Improve Detection of Clinically Relevant Microorganisms. J Clin Microbiol. 2016;54(5):1216-22.
- ARC. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. The Lancet. 2022;399:629–655.
- Szlachta-McGinn A, et al. Molecular Diagnostic Methods Versus Conventional Urine Culture for Diagnosis and Treatment of Urinary Tract Infection: A Systematic Review and Meta-analysis. Eur Urol Open Sci. 2022;44:113-124.
- Couto-Rodriguez M, et al. Analytical Validation of a Highly Accurate and Reliable Next-Generation Sequencing-Based Urine Assay. medRxiv. 2024.
- Romero EJM, et al. Utilization of Clinical-Grade Metagenomics in Urinary Tract Infection Diagnostics: Improving High-Risk Patients' Outcomes with a Genomic-Based Assay. Open Forum Infect Dis. 2023;10:ofad500.2445.
- Wangprapa P, et al. BIOTIA-DX Validation in an Asian Cohort: Implementation in a Private Thai Tertiary Hospital. Unpublished.
- Fidler G, et al. Comprehensive Next-Generation Sequencing-Based Assay for Antimicrobial Resistance Gene Marker Identification in Urine. Open Forum Infect Dis. 2025;12:ofae631.2319.